康禧全球投資基金是一家專注於醫藥醫療行業投資的基金公司,在藥物治療和醫療器械領域針對大中華區的增長平台和美國的相關創新進行投資。康禧支持這類公司的發展並致力於從其相互合作中創造附加價值,從而實現回報。憑藉在大中華區和美國的豐富專業知識和經驗,康禧相信自己具有助力此類合作的有利條件。





康禧計劃通過多種投資類型和交易結構進行投資,包括後期風險投資(已完成概念驗證)、企業成長資本、直接或間接的私募股權投資、併購投資、戰略性投資、重組以及涉及上市公司的再融資和投資。以上述的投資類型作為基礎,本基金可能單獨進行投資,或在某項由另一個投資者發起和操作的交易中進行共同投資。





康禧於2014年成立,創始人為尹衍樑博士、張念慈博士、陳志全先生和陳林正先生,由陳林正先生任管理合夥人。

Delos Capital                                     康禧全球投資基金

Delos Capital is a healthcare-focused fund, investing in growth platforms in Greater China and relevant innovation in the US in both therapeutics and medical technology areas.  Delos Capital seeks to achieve returns through supporting these companies in their development and also helping to create additional value from collaboration between these companies.  With the extensive expertise and experience in both Greater China and the US, Delos Capital believes that it is well positioned to help with such collaboration.   


Delos Capital plans to make investments through a broad variety of types and transaction structures, including late-stage developments (with proof of concept), growth capital, direct or indirect private equity investments, buyout investments, strategic investments, restructurings and recapitalizations and investments in publicly listed securities.  In connection with the foregoing, the Partnership may make its investments either alone or jointly in a transaction originated and led by another investor. 

Managed by Henry Chen, Delos Capital was established in 2014 by founding partners Dr. Samuel Yin, Dr. Michael Chang, Frank Chen and Henry Chen.